FTC Approves Final Order Imposing Conditions on Merger of Generic Drug Marketers Amneal Pharmaceuticals LLC and Impax Laboratories Inc.

Following a public comment period, the Federal Trade Commission has approved a final order settling charges that Amneal’s $1.45 billion acquisition of an equity share in Impax likely would be anticompetitive.

According to the complaint, which was first announced in April 2018, the acquisition likely would harm current competition in U.S. markets for three generic products: desipramine hydrochloride tablets; ezetimibe and simvastatin immediate release tablets; and felbamate tablets.

The acquisition also likely would harm future competition in U.S. markets for seven generic products: aspirin and dipyridamole extended release capsules; azelastine nasal spray; diclofenac sodium and misoprostol delayed release tablets; erythromycin tablets; fluocinonide-E cream; methylphenidate hydrochloride extended release tablets; and olopatadine hydrochloride nasal spray.

Under the settlement, ANI Pharmaceuticals, Inc. will acquire seven products. Perrigo Company plc will acquire Impax’s rights to two products that it had partnered with Impax to develop, manufacture, and sell. G&W Laboratories will acquire Impax’s marketing rights to one product that G&W manufactures for Impax.

The Commission vote approving the final order was 5-0. (The staff contact is Kari Wallace, Bureau of Competition, 202-326-3085)

The Federal Trade Commission works to promote competition, and protect and educate consumers. You can learn more about how competition benefits consumers or file an antitrust complaint. Like the FTC on Facebook, follow us on Twitter, read our blogs and subscribe to press releases for the latest FTC news and resources.

IR Press

Recent Posts

Treasury Issues Final Rule Expanding CFIUS Coverage of Real Estate Transactions Around More Than 60 Military Installations

WASHINGTON – Today, the U.S. Department of the Treasury (Treasury), as Chair of the Committee…

2 days ago

U.S. Department of the Treasury’s CDFI Fund and Federal Housing Finance Agency Collaborate to Bolster CDFI Access to Capital

WASHINGTON—Today, the U.S. Department of the Treasury’s Community Development Financial Institutions Fund (CDFI Fund) and…

2 days ago

Report on U.S. Portfolio Holdings of Foreign Securities at Year-End 2023

Washington – The findings from the annual survey of U.S. portfolio holdings of foreign securities…

3 days ago

READOUT: U.S. Department of the Treasury Hosts Roundtable Discussion on the Financial Sector’s Response to Recent Hurricanes

WASHINGTON – The U.S. Department of the Treasury hosted a roundtable on October 30 with…

3 days ago

READOUT: Sixth Meeting of the Financial Working Group Between the United States and the People’s Republic of China

WASHINGTON – The United States and the People’s Republic of China held the sixth meeting…

3 days ago

Treasury Sanctions Key Members of La Linea, a Group Involved in Trafficking Fentanyl into the United States

WASHINGTON — Today, the Department of the Treasury’s Office of Foreign Assets Control (OFAC) sanctioned…

3 days ago